Skip to main content
Xiangxue Pharmaceutical Co., Ltd. logo

Xiangxue Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 300147 ISIN · CNE100000Y92 LEI · 3003000D8UMO4KQ95B57 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,287 across all filing types
Latest filing 2023-08-02 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 300147

About Xiangxue Pharmaceutical Co., Ltd.

https://www.xphcn.com

Xiangxue Pharmaceutical Co., Ltd. specializes in the research, development, manufacturing, and distribution of modern Traditional Chinese Medicine (TCM), chemical drugs, and biological products. The company is recognized for its focus on the modernization of TCM, utilizing advanced technology to standardize and enhance traditional formulas. Its flagship products include anti-viral oral liquids and Banlan'gen granules, which are widely used for respiratory health. Beyond traditional treatments, the company has expanded into high-tech biomedical fields, including precision medicine and adoptive cell therapy, specifically TCR-T cell technology for cancer treatment. Xiangxue operates a comprehensive value chain encompassing medicinal herb cultivation, pharmaceutical manufacturing, and healthcare services. By integrating digital technology with pharmaceutical expertise, the company aims to provide integrated health solutions and innovative therapies.

Recent filings

Filing Released Lang Actions
关于转让参股公司股权暨关联交易的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding the transfer of equity in an associated company, including information about the transaction parties, pricing, audit and valuation reports, board approvals, and risk disclosures. It involves a related party transaction and includes financial data from audit and valuation reports but is primarily focused on the announcement of the equity transfer and related corporate actions. It is not a full annual or interim financial report, nor a management discussion or earnings release. The document is too detailed and lengthy to be a simple announcement of report publication. It fits best as a Capital/Financing Update (CAP) because it concerns a significant equity transfer and related financing arrangements by the company.
2023-08-02 Chinese
湖北天济药业有限公司审计报告
Audit Report / Information Classification · 100% confidence The document is titled as an "审计报告" (Audit Report) for 湖北天济药业有限公司 covering the period from January 1, 2023 to June 30, 2023. It includes detailed audit opinions, financial statements such as consolidated balance sheets, profit and loss statements, cash flow statements, and notes to the financial statements. The presence of an auditor's opinion, detailed financial data, and extensive notes indicates this is a standalone audit report rather than a full annual report or an announcement. The document length is substantial (15,000 characters) and contains actual financial data, not just a certification or announcement. Therefore, it fits the category of Audit Report / Information (AR). H1 2023
2023-08-02 Chinese
关于完成工商变更登记并换发营业执照的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the completion of business registration changes and issuance of a new business license. It details changes in the company's registered address, business scope, and amendments to the company charter. There is no financial data, no mention of financial results, no audit information, no voting results, no executive changes, no legal proceedings, and no investor presentation content. The document is short (987 characters) and is an official announcement of a corporate administrative update. This fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2023-07-19 Chinese
关于公司被申请强制执行的公告
Legal Proceedings Report Classification · 95% confidence The document is a public announcement by Guangzhou Xiangxue Pharmaceutical Co., Ltd. regarding the company being subject to compulsory enforcement actions by courts due to unpaid debts and related litigation/arbitration matters. It details the enforcement case numbers, amounts, involved parties, and the company's response and risk disclosures. The document does not contain financial statements, audit results, or detailed financial performance data. It is a regulatory announcement about legal and financial risks and enforcement proceedings, not a full audit report, annual report, or earnings release. The document length is short (2154 characters) and it is a standalone announcement about legal proceedings and enforcement, fitting best under Legal Proceedings Report (LTR).
2023-07-07 Chinese
关于涉及重大诉讼案进展的公告
Legal Proceedings Report Classification · 95% confidence The document is an announcement from Guangzhou Xiangxue Pharmaceutical Co., Ltd. regarding the progress of a significant litigation case involving a dispute over equity transfer. It details the court's civil judgment, the obligations of the company, and the potential financial impact. The document does not contain financial statements or detailed financial analysis but provides legal and litigation updates. It is not a full audit report or annual report but a legal proceeding update. Therefore, it fits the category of Legal Proceedings Report (LTR). The document length is 1565 characters, which is consistent with an announcement rather than a full report.
2023-06-30 Chinese
关于向银行申请贷款的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Guangzhou Xiangxue Pharmaceutical Co., Ltd. regarding the company's application for a bank loan. It details the approval of loan proposals by the board, the amount of the loan, guarantees, and the purpose of the loan. There is no financial statement or detailed financial report included. The document is focused on financing activities and capital structure changes. The length is short (874 characters), and it is not a report but an announcement of a financing event. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2023-06-30 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.